Clinical Trials

  • A photo of BridgeBio Pharma CEO Neil Kumar
    Image attribution tooltip
    Permission granted by BridgeBio Pharma
    Image attribution tooltip

    BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis

    The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

    By • Updated Feb. 12, 2026
  • An illustration of stock market quotes.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study

    The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent. 

    By • Feb. 10, 2026
  • Brain scans of a person with Alzheimer's are seen in this conceptual image. Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Neuroscience drug development

    Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

    By BioPharma Dive staff
  • A headshot of Ron Renaud, the CEO of Kailera Therapeutics.
    Image attribution tooltip
    Permission granted by Kailera Therapeutics
    Image attribution tooltip
    Obesity drugs

    Hengrui, Kailera tout positive results for dual-acting obesity pill

    Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could eventually become a “differentiated treatment option” compared to other obesity pills.

    By • Feb. 9, 2026
  • Illustration of a blood clot blocking red blood cells within an artery or a vein.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bayer details anticipated stroke prevention data for new blood-thinner

    Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

    By • Feb. 5, 2026
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Pfizer dips on new data for obesity drug acquired in $10B deal

    A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

    By • Feb. 3, 2026
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo combination obesity shot meets goal in diabetes trial

    CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.

    By • Feb. 2, 2026
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

    The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

    By • Feb. 2, 2026
  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen gives up on its once-prized eczema drug

    The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent. 

    By • Jan. 30, 2026
  • Intellia Therapeutics headquarters in Cambridge, MA
    Image attribution tooltip
    Courtesy of Intellia Therapeutics
    Image attribution tooltip
    Gene editing

    FDA lifts hold on an Intellia CRISPR drug trial

    Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

    By • Jan. 27, 2026
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Obesity drugs

    Roche, trailing in obesity, showcases new data for GLP-1 shot

    A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

    By • Jan. 27, 2026
  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time

    On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.

    By • Jan. 26, 2026
  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    Sanofi to seek approval of touted eczema drug despite mixed results

    Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.

    By • Jan. 23, 2026
  • A modern architectural design building featuring a red-brick façade with large glass windows displays a prominent sign of the Food and Drug Administration.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    FDA lays out new path to speed development of multiple myeloma drugs

    In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines. 

    By • Jan. 22, 2026
  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Corvus shares nearly triple on positive data for eczema pill

    While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

    By • Jan. 21, 2026
  • A woman sits on a sofa, holding a smartphone, appearing thoughtful. She's surrounded by plants, with a relaxed, cozy atmosphere in warm lighting.
    Image attribution tooltip

     

    1nHealth

    Image attribution tooltip
    Sponsored by 1nHealth

    The patient retention crisis is happening before enrollment even begins

    The biggest patient drop-off happens before patients ever enroll.

    By Katie Rodammer • Jan. 20, 2026
  • Person standing up and speaking to a board room full of people.
    Image attribution tooltip
    Permission granted by Almac Clinical Services
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    When every day counts: Building CRO partnerships on a foundation of trust, care and precision

    Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients. 

    Jan. 20, 2026
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tecvayli tops standard drugs in early multiple myeloma, J&J says

    The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher. 

    By • Jan. 15, 2026
  • Sanofi
    Image attribution tooltip
    Permission granted by Sanofi
    Image attribution tooltip

    What Sanofi’s multiple sclerosis troubles could mean for the space

    Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.

    By Kelly Bilodeau • Jan. 13, 2026
  • medical scientists analyzing research scans on a computer,
    Image attribution tooltip
    Sean Anthony Eddy via Getty Images
    Image attribution tooltip
    Sponsored by Pearson

    Best practices for COA selection: Building a stronger foundation for clinical trials

    In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward efficiently while maintaining scientific and regulatory rigor.

    Jan. 12, 2026
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK, Ionis claim study success for RNA-based hepatitis B drug

    The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

    By Kristin Jensen • Jan. 7, 2026
  • African American Woman With Itchy Skin. Allergy Or Psoriasis
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Alumis soars as TYK2 drug hits mark in psoriasis trials

    Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.

    By • Jan. 6, 2026
  • Wall street sign in New York City with New York Stock Exchange background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Zenas shares crash after top drug misses expectations in immune disease study

    While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.

    By • Jan. 5, 2026
  • Doctors checking charts on computer screen
    Image attribution tooltip
    Permission granted by LifeLabs
    Image attribution tooltip
    Sponsored by LifeLabs

    Strategic diagnostic testing partnerships are accelerating clinical research

    With the rise of biologics, precision medicine and AI-driven drug discovery, clinical research has entered a new and complex era.

    Jan. 5, 2026
  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Tracker

    10 clinical trials to watch in the first half of 2026

    After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.

    By BioPharma Dive staff • Jan. 5, 2026
  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Patient deaths put Merck, Daiichi’s ADC trial on partial hold

    The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” in people with small cell lung cancer.

    By • Dec. 19, 2025